KLRC1 and neoplasm: However, unlike PD-1 that was also expressed in other immune cells including Tregs, expression of NKG2A was tightly restricted to cytotoxic T and NK cells, suggesting that NKG2A might be a novel target for the delivery of an IL-2βγ agonist to orchestrate both cytotoxic T and NK cells for tumor immunotherapy.